Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its sANDA for Levothyroxine Sodium Tablets USP from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of LEVOXYL® 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg,150 mcg, 175 mcg, 200 mcg, and 300 mcg, manufactured by King Pharmaceuticals Research and Development LLC.

Lupin’s Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg was originally approved on January 18, 2019 as generic equivalent of SYNTHROID® manufactured by ABBVIE Inc.

Earlier, Lupin also received sANDA approval dated September 19, 2019 for its Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg,  88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of UNITHROID®  manufactured by Jerome Stevens Pharmaceuticals Inc.

With this sANDA approval, Lupin’s Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg,  88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg are now AB rated (therapeutically equivalent) with Reference Listed Drugs, SYNTHROID®, UNITHROID® and LEVOXYL® and are the only product approved with FDA’s new Narrow Therapeutic Index guidance for Levothyroxine.

Lupin’s Levothyroxine Sodium Tablets are indicated for:

• Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism
• Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer

Cumulatively, Levothyroxine Sodium Tablets USP (RLDs: SYNTHROID®, UNITHROID® and LEVOXYL®) had annual sales of approximately USD 2,581 million in the US (IQVIA MAT June 2019).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8^thlargest generics pharmaceutical company by revenues (31^stMar 2019, Bloomberg LTM) respectively. The Company is the 3^rdlargest pharmaceutical player in the US by prescriptions (IQVIA MAT Jun 2019); 3^rdlargest Indian pharmaceutical company by global revenues (31^stMar 2019, Bloomberg LTM); 5^thlargest generic pharmaceutical player in Japan and 6^thlargest company in the Indian Pharmaceutical Market (IQVIA MAT Jun 2019).

For the financial year ended 31^stMarch 2019, Lupin’s Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Arvind Bothra
Head – Investor Relations and M&A / Corporate Communications
Email: arvindbothra@lupin.com
Ph: +91-22-66408237

*Safe Harbor Statement

LEVOXYL®is the registered trademark of King Pharmaceuticals Research and Development LLC.

UNITHROID®is the registered trademark of Jerome Stevens Pharmaceuticals Inc.

SYNTHROID® is the registered trademark of AbbVie Inc.